uniQure N.V. (NASDAQ:QURE) Receives $65.00 Consensus Price Target from Brokerages

uniQure N.V. (NASDAQ:QURE) has been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $65.00.

Several research analysts have weighed in on the company. Stifel Nicolaus set a $28.00 price objective on uniQure in a research report on Tuesday, May 5th. Wells Fargo & Company lifted their target price on uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. The Goldman Sachs Group lifted their target price on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Finally, Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a report on Saturday, August 1st.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 164,429 shares of uniQure stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the sale, the chief executive officer owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 388,229 shares of company stock worth $16,817,099. 4.65% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP boosted its position in uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the period. Legal & General Group Plc bought a new stake in shares of uniQure in the second quarter valued at approximately $497,000. Marshall Wace LLP lifted its stake in shares of uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after buying an additional 163,749 shares in the last quarter. California State Teachers Retirement System purchased a new stake in shares of uniQure during the 2nd quarter valued at approximately $540,000. Finally, Ameriprise Financial Inc. boosted its holdings in uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Down 2.3%

QURE opened at $45.00 on Friday. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The firm has a market capitalization of $3.12 billion, a P/E ratio of -11.22 and a beta of 0.92. The company’s 50-day moving average is $40.13 and its 200 day moving average is $27.40. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same period in the prior year, the business earned ($0.69) EPS. Research analysts expect that uniQure will post -3.74 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.